Loading...

Zelda Therapeutics

ASX:ZLD
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZLD
ASX
A$34M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The last earnings update was 91 days ago. More info.


Add to Portfolio Compare Print
  • Zelda Therapeutics has significant price volatility in the past 3 months.
ZLD Share Price and Events
7 Day Returns
-2.2%
ASX:ZLD
1.6%
AU Biotechs
2.5%
AU Market
1 Year Returns
-59.1%
ASX:ZLD
13.6%
AU Biotechs
5%
AU Market
ZLD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zelda Therapeutics (ZLD) -2.2% -6.3% -16.7% -59.1% - -
AU Biotechs 1.6% 8.5% 11.5% 13.6% 76.6% 166.2%
AU Market 2.5% 2.4% 4.8% 5% 19.3% 8.7%
1 Year Return vs Industry and Market
  • ZLD underperformed the Biotechs industry which returned 13.6% over the past year.
  • ZLD underperformed the Market in Australia which returned 5% over the past year.
Price Volatility
ZLD
Industry
5yr Volatility vs Market

Value

 Is Zelda Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Zelda Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is A$0.045.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zelda Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zelda Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ZLD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:ZLD Share Price ** ASX (2019-05-24) in AUD A$0.05
Global Biotechs Industry PE Ratio Median Figure of 76 Publicly-Listed Biotechs Companies 20.48x
Australia Market PE Ratio Median Figure of 542 Publicly-Listed Companies 16.39x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zelda Therapeutics.

ASX:ZLD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ZLD Share Price ÷ EPS (both in AUD)

= 0.05 ÷ 0.00

-10.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zelda Therapeutics is loss making, we can't compare its value to the Global Biotechs industry average.
  • Zelda Therapeutics is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Zelda Therapeutics's expected growth come at a high price?
Raw Data
ASX:ZLD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 57 Publicly-Listed Biotechs Companies 1.23x
Australia Market PEG Ratio Median Figure of 358 Publicly-Listed Companies 1.43x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Zelda Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Zelda Therapeutics's assets?
Raw Data
ASX:ZLD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:ZLD Share Price * ASX (2019-05-24) in AUD A$0.05
Australia Biotechs Industry PB Ratio Median Figure of 43 Publicly-Listed Biotechs Companies 2.89x
Australia Market PB Ratio Median Figure of 1,680 Publicly-Listed Companies 1.66x
ASX:ZLD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ZLD Share Price ÷ Book Value per Share (both in AUD)

= 0.05 ÷ 0.01

7.95x

* Primary Listing of Zelda Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zelda Therapeutics is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Zelda Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Zelda Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Zelda Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zelda Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.1%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zelda Therapeutics expected to grow at an attractive rate?
  • Unable to compare Zelda Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Zelda Therapeutics's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Zelda Therapeutics's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:ZLD Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 10.1%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 8.7%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.9%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ZLD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ZLD Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -3 -3
2018-09-30 0 -3 -3
2018-06-30 0 -3 -2
2018-03-31 0 -3 -2
2017-12-31 0 -3 -2
2017-09-30 0 -2 -4
2017-06-30 0 -2 -6
2016-12-31 0 -1 -5
2016-06-30 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Zelda Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Zelda Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ZLD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Zelda Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ZLD Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 -0.01
2017-06-30 -0.01
2016-12-31 -0.04
2016-06-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zelda Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Zelda Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Zelda Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Zelda Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Zelda Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zelda Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Zelda Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zelda Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zelda Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Zelda Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Zelda Therapeutics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Zelda Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zelda Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ZLD Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.24 -3.30 1.06 2.17
2018-09-30 0.27 -2.51 0.97 1.98
2018-06-30 0.31 -1.73 0.87 1.79
2018-03-31 0.29 -1.67 0.96 1.59
2017-12-31 0.18 -1.61 1.05 1.39
2017-09-30 0.14 -3.88 1.45 1.03
2017-06-30 0.10 -6.16 1.84 0.67
2016-12-31 0.05 -5.47 1.59 0.10
2016-06-30 0.30 -0.27 0.45 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Zelda Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Zelda Therapeutics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Zelda Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Zelda Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zelda Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Zelda Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zelda Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zelda Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zelda Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zelda Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Zelda Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zelda Therapeutics Company Filings, last reported 4 months ago.

ASX:ZLD Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.27 0.00 4.41
2018-09-30 4.27 0.00 4.41
2018-06-30 6.21 0.00 5.69
2018-03-31 6.21 0.00 5.69
2017-12-31 7.42 0.00 6.69
2017-09-30 7.42 0.00 6.69
2017-06-30 7.90 0.00 7.87
2016-12-31 3.33 0.21 3.80
2016-06-30 -0.22 1.00 0.72
  • Zelda Therapeutics has no debt.
  • Zelda Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Zelda Therapeutics has sufficient cash runway for 1.7 years based on current free cash flow.
  • Zelda Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 40.9% each year.
X
Financial health checks
We assess Zelda Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zelda Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Zelda Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Zelda Therapeutics dividends.
If you bought A$2,000 of Zelda Therapeutics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Zelda Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Zelda Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ZLD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
Australia Market Average Dividend Yield Market Cap Weighted Average of 414 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Zelda Therapeutics has not reported any payouts.
  • Unable to verify if Zelda Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Zelda Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Zelda Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Zelda Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zelda Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zelda Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Zelda Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Hopkins
AGE 51
TENURE AS CEO 0.8 years
CEO Bio

Dr. Richard Miles Hopkins, Bsc (Hons), Ph.D. is Managing Director and Director at Zelda Therapeutics Ltd since July 16, 2018. Mr. Hopkins served as the Chief Executive Officer of PharmAust Limited since March 07, 2017 until May 25, 2018. Dr. Hopkins served as the Chief Executive Officer of Phylogica Limited from July 19, 2013 to October 2016 and served as its Chief Operating Officer until July 19, 2013. He served as the Chief Scientific Officer of Phylogica Limited. He was a co-founder of Phylogica and Vice President of Research. He is an experienced pharmaceutical executive with over 10 years in corporate leadership roles. His most recent research is focussed on engineering peptide leads for drug development. He has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe. He carried out postdoctoral research in yeast genetics at the Telethon Institute for Child Health Research, Perth, Western Australia and the Department of Medicine at the University of Western Australia and Murdoch University. His research focused on the development of a novel class of peptides, trademarked by Phylogica as Phylomers® and the methods to integrate them into various high throughput screening platforms such as yeast- two-hybrid and phage display. Dr. Hopkins was elected to the position of Chair of Ausbiotech (WA Branch) in 2016. Dr. Hopkins served as an Executive Director of Phylogica Limited from July 19, 2013 to July 18, 2016. He has a BSc (Hons) and completed a PhD in Molecular Parasitiology.

CEO Compensation
  • Insufficient data for Richard to compare compensation growth.
  • Insufficient data for Richard to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Zelda Therapeutics management team in years:

4.3
Average Tenure
51
Average Age
  • The tenure for the Zelda Therapeutics management team is about average.
Management Team

Mara Gordon

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
A$36K
AGE
58
TENURE
4.3 yrs

Jason Peterson

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
A$36K
TENURE
4.3 yrs

Stewart Washer

TITLE
Co-Founder & Executive Director
COMPENSATION
A$234K
AGE
48
TENURE
4.3 yrs

Richard Hopkins

TITLE
MD & Director
AGE
51
TENURE
0.8 yrs

Tim Slate

TITLE
Company Secretary
TENURE
2.4 yrs

Patty Washer

TITLE
Clinical Trial Consultant
Board of Directors Tenure

Average tenure and age of the Zelda Therapeutics board of directors in years:

2.5
Average Tenure
49.5
Average Age
  • The average tenure for the Zelda Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Harry Karelis

TITLE
Co-Founder & Non-Executive Chairman
COMPENSATION
A$300K
AGE
48

Mara Gordon

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
A$36K
AGE
58
TENURE
2.5 yrs

Jason Peterson

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
A$36K
TENURE
2.5 yrs

Stewart Washer

TITLE
Co-Founder & Executive Director
COMPENSATION
A$234K
AGE
48
TENURE
2.5 yrs

Richard Hopkins

TITLE
MD & Director
AGE
51

Manuel Guzman

TITLE
Member of Medical Advisory Board

Cristina Sanchez

TITLE
Member of Medical Advisory Board

Joe Goldstrich

TITLE
Member of Medical Advisory Board
TENURE
3.3 yrs

Noah Federman

TITLE
Member of Medical Advisory Board
TENURE
3.2 yrs

David Casarett

TITLE
Scientific & Medical Advisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Zelda Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zelda Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Zelda Therapeutics Limited (ASX:ZLD) Can Impact Your Portfolio Volatility

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Do Insiders Own Lots Of Shares In Zelda Therapeutics Limited (ASX:ZLD)?

A look at the shareholders of Zelda Therapeutics Limited (ASX:ZLD) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Zelda Therapeutics is not a large company by global standards.

Simply Wall St -

Are Zelda Therapeutics Limited's (ASX:ZLD) Interest Costs Too High?

The direct benefit for Zelda Therapeutics Limited (ASX:ZLD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

What Type Of Shareholder Owns Zelda Therapeutics Limited's (ASX:ZLD)?

The big shareholder groups in Zelda Therapeutics Limited (ASX:ZLD) have power over the company. … With a market capitalization of AU$45m, Zelda Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Zelda Therapeutics

Simply Wall St -

Why Zelda Therapeutics Limited's (ASX:ZLD) Ownership Structure Is Important

I am going to take a deep dive into Zelda Therapeutics Limited’s (ASX:ZLD) most recent ownership structure, not a frequent subject of discussion among individual investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … Therefore, it is beneficial for us to examine ZLD's ownership structure in more detail.

Simply Wall St -

Are Earnings Prospects Improving For Loss-Making Zelda Therapeutics Limited's (ASX:ZLD)?

Today I will take a look at Zelda Therapeutics Limited's (ASX:ZLD) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past few years, as well as how the rest of the biotechs industry performed. … View our latest analysis for Zelda Therapeutics Did ZLD's recent earnings growth beat the long-term trend and the industry? … For Zelda Therapeutics, its most recent earnings (trailing twelve month) is -AU$1.61M, which, against the prior year's figure, has become less negative.

Simply Wall St -

Should You Be Concerned About Zelda Therapeutics Limited's (ASX:ZLD) Investors?

I am going to take a deep dive into Zelda Therapeutics Limited’s (ASX:ZLD) most recent ownership structure, not a frequent subject of discussion among individual investors. … Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Thus, investors should dig deeper into ZLD's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in ZLD need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

Zelda Therapeutics Limited (ASX:ZLD): Is Healthcare Attractive Relative To ASX Peers?

Today, I will analyse the industry outlook, and also determine whether Zelda Therapeutics is a laggard or leader relative to its healthcare sector peers. … As the company trails the rest of the industry in terms of growth, Zelda Therapeutics may also be a cheaper stock relative to its peers. … Next Steps: Zelda Therapeutics has been a biotech industry laggard in the past year.

Simply Wall St -

Who Owns Zelda Therapeutics Limited (ASX:ZLD)?

While these are more of a long-term investor’s concern, short-term investors may find the impact of institutional trading overwhelming enough to lose out on what could be a potential opportunity. … View our latest analysis for Zelda Therapeutics ASX:ZLD Ownership Summary Nov 11th 17 Institutional Ownership Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions.

Simply Wall St -

Is Zelda Therapeutics Limited (ASX:ZLD) Still A Cheap Healthcare Stock?

ASX:ZLD PE PEG Gauge Oct 20th 17 The biotech industry is trading at a PE ratio of 31x, above the broader Australian stock market PE of 16x. … If your initial investment thesis is around the growth prospects of ZLD, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its biotech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

Company Info

Description

Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoids to treat diabetes-associated cognitive decline. Zelda Therapeutics Limited has strategic partnership with CannPal Pty Ltd.; and St Vincent's Hospital on opioid reduction study. The company is based in Perth, Australia.

Details
Name: Zelda Therapeutics Limited
ZLD
Exchange: ASX
Founded:
A$33,990,387
755,341,934
Website: http://www.zeldatherapeutics.com
Address: Zelda Therapeutics Limited
140 St George's Terrace,
Level 26,
Perth,
Western Australia, 6000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ZLD Ordinary Shares Australian Securities Exchange AU AUD 22. Nov 2016
OTCPK ZLDA.F Ordinary Shares Pink Sheets LLC US USD 22. Nov 2016
DB G1G Ordinary Shares Deutsche Boerse AG DE EUR 22. Nov 2016
CHIA ZLD Ordinary Shares Chi-X Australia AU AUD 22. Nov 2016
Number of employees
Current staff
Staff numbers
0
Zelda Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 10:36
End of day share price update: 2019/05/24 00:00
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.